204 related articles for article (PubMed ID: 2897960)
1. Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
Boza RA; Milanes F; Starkey T; Slater V; Dominguez F
J Clin Psychiatry; 1988 Jun; 49(6):245. PubMed ID: 2897960
[No Abstract] [Full Text] [Related]
2. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
Jayaram G; Coyle J; Tune L
J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
[TBL] [Abstract][Full Text] [Related]
3. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
Brown WA; Silver MA
J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
[TBL] [Abstract][Full Text] [Related]
4. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia.
Leong OK; Wong KE; Tay WK; Gill RC
Singapore Med J; 1989 Oct; 30(5):436-40. PubMed ID: 2575796
[TBL] [Abstract][Full Text] [Related]
6. Low serum neuroleptic levels predict relapse in schizophrenic patients.
Brown WA; Laughren T; Chisholm E; Williams BW
Arch Gen Psychiatry; 1982 Sep; 39(9):998-1000. PubMed ID: 6126172
[TBL] [Abstract][Full Text] [Related]
7. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
Faraone SV; Brown WA; Laughren TP
J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
[TBL] [Abstract][Full Text] [Related]
8. Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.
Hogarty GE
J Clin Psychiatry; 1984 May; 45(5 Pt 2):36-42. PubMed ID: 6143746
[TBL] [Abstract][Full Text] [Related]
9. The dysphoric syndrome in schizophrenia and its implications for relapse.
Hirsch SR; Jolley AG
Br J Psychiatry Suppl; 1989 Jul; (5):46-50. PubMed ID: 2690890
[No Abstract] [Full Text] [Related]
10. Expressed emotion, fixed-dose fluphenazine decanoate maintenance, and relapse in recent-onset schizophrenia.
Nuechterlein KH; Snyder KS; Dawson ME; Rappe S; Gitlin M; Fogelson D
Psychopharmacol Bull; 1986; 22(3):633-9. PubMed ID: 3797570
[No Abstract] [Full Text] [Related]
11. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse.
Steingard S; Allen M; Schooler NR
J Clin Psychiatry; 1994 Nov; 55(11):470-2. PubMed ID: 7989278
[TBL] [Abstract][Full Text] [Related]
12. A comparative study with pipothiazine palmitate and fluphenazine enanthate in the treatment of schizophrenic patients.
Jain RC; Ananth JV; Lehmann HE; Ban TA
Curr Ther Res Clin Exp; 1975 Oct; 18(4):585-9. PubMed ID: 241609
[No Abstract] [Full Text] [Related]
13. Early hospital experience with fluphenazine decanoate.
Small JG; Kellams J
Dis Nerv Syst; 1974 Oct; 35(10):453-6. PubMed ID: 17894058
[TBL] [Abstract][Full Text] [Related]
14. The use of depot neuroleptics: clinical experience in the United States.
Kane JM
J Clin Psychiatry; 1984 May; 45(5 Pt 2):5-12. PubMed ID: 6370987
[TBL] [Abstract][Full Text] [Related]
15. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
Odejide OA; Aderounmu AF
J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
[TBL] [Abstract][Full Text] [Related]
16. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
Chouinard G; Annable L; Ross-Chouinard A
Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
[No Abstract] [Full Text] [Related]
17. Serum neuroleptic levels in the maintenance treatment of schizophrenia.
Brown WA; Laughren T
Psychopharmacol Bull; 1983; 19(1):76-8. PubMed ID: 6131471
[No Abstract] [Full Text] [Related]
18. Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics.
Mandel MR; Severe JB; Schooler NR; Gelenberg AJ; Mieske M
Arch Gen Psychiatry; 1982 Feb; 39(2):197-203. PubMed ID: 6121543
[TBL] [Abstract][Full Text] [Related]
19. Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
Douyon R; Angrist B; Peselow E; Cooper T; Rotrosen J
Am J Psychiatry; 1989 Feb; 146(2):231-4. PubMed ID: 2563211
[TBL] [Abstract][Full Text] [Related]
20. Neuroleptic levels by radioreceptor assay and clinical response during treatment of acute exacerbation of schizophrenia--some preliminary findings.
Greenberg JS; Brown WA; Laughren TP; Krantz J
Psychopharmacol Bull; 1983; 19(1):74-6. PubMed ID: 6131470
[No Abstract] [Full Text] [Related]
[Next] [New Search]
